Critical Comparison: Aclarion (ACON) & Its Rivals

Aclarion (NASDAQ:ACON) is one of 93 public companies in the “Medical Services” industry, but how does it contrast to its peers? We will compare Aclarion to similar businesses based on the strength of its risk, analyst recommendations, dividends, earnings, valuation, profitability and institutional ownership.

Insider and Institutional Ownership

7.5% of Aclarion shares are held by institutional investors. Comparatively, 58.1% of shares of all “Medical Services” companies are held by institutional investors. 0.8% of Aclarion shares are held by company insiders. Comparatively, 13.2% of shares of all “Medical Services” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Aclarion and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Aclarion	$50,000.00	-$6.99 million	-0.41
Aclarion Competitors	$9.91 billion	$239.88 million	13.57

Aclarion’s peers have higher revenue and earnings than Aclarion. Aclarion is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Aclarion and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1	1	0	0	1.50
Aclarion Competitors	640	2502	5135	184	2.57

Aclarion presently has a consensus price target of $11,758.50, suggesting a potential upside of 192,032.35%. As a group, “Medical Services” companies have a potential upside of 13.97%. Given Aclarion’s higher probable upside, equities research analysts plainly believe Aclarion is more favorable than its peers.

Profitability

This table compares Aclarion and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,908.50%	-67.53%	-63.01%
Aclarion Competitors	-974.48%	-66.47%	-17.52%

Volatility and Risk

Aclarion has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Aclarion’s peers have a beta of 1.53, meaning that their average stock price is 53% more volatile than the S&P 500.

Summary

Aclarion peers beat Aclarion on 12 of the 13 factors compared.

Aclarion Company Profile

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.